TACSTD2 and prostate cancer: Thus, our results suggest that extracellular TROP2 expression could serve as a prognostic indicator of treatment outcome in prostate cancer, and that targeting cancer cells with high surface expression of TROP2 may be an effective way to prevent progression towards castration resistant prostate cancer.